Media stories about Axsome Therapeutics (NASDAQ:AXSM) have trended somewhat positive this week, according to Accern. The research group rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Axsome Therapeutics earned a news sentiment score of 0.16 on Accern’s scale. Accern also assigned news articles about the company an impact score of 46.5744411885076 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Shares of Axsome Therapeutics stock opened at $2.70 on Thursday. Axsome Therapeutics has a 52-week low of $2.45 and a 52-week high of $6.45. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.90 and a quick ratio of 2.90.
Axsome Therapeutics (NASDAQ:AXSM) last issued its earnings results on Wednesday, March 7th. The company reported ($0.28) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.32) by $0.04. equities research analysts anticipate that Axsome Therapeutics will post -0.26 EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Axsome Therapeutics (AXSM) Share Price” was originally reported by BBNS and is the sole property of of BBNS. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://baseballnewssource.com/2018/03/22/axsome-therapeutics-axsm-given-daily-media-impact-rating-of-0-16/1926423.html.
About Axsome Therapeutics
Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain.
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.